Revance Therapeutics (RVNC) to Release Quarterly Earnings on Thursday

Revance Therapeutics (NASDAQ:RVNC) is scheduled to announce its earnings results after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.12. The business had revenue of $51.94 million during the quarter, compared to analyst estimates of $55.64 million. On average, analysts expect Revance Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Revance Therapeutics Trading Up 1.6 %

Shares of RVNC traded up $0.05 during mid-day trading on Tuesday, reaching $3.11. The company’s stock had a trading volume of 815,806 shares, compared to its average volume of 1,881,667. Revance Therapeutics has a 1-year low of $2.30 and a 1-year high of $23.02. The stock has a market cap of $324.84 million, a P/E ratio of -0.84 and a beta of 0.98. The business has a 50-day simple moving average of $3.10 and a two-hundred day simple moving average of $4.19.

Wall Street Analysts Forecast Growth

RVNC has been the subject of several research reports. Needham & Company LLC dropped their price target on Revance Therapeutics from $18.00 to $12.00 and set a “buy” rating for the company in a report on Friday, May 10th. Mizuho dropped their price target on Revance Therapeutics from $9.00 to $8.00 and set a “neutral” rating for the company in a report on Friday, May 10th. HC Wainwright dropped their price target on Revance Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a report on Monday, May 13th. Piper Sandler reissued an “overweight” rating and set a $11.00 price target (down from $20.00) on shares of Revance Therapeutics in a report on Friday, May 10th. Finally, The Goldman Sachs Group dropped their price target on Revance Therapeutics from $9.00 to $8.00 and set a “neutral” rating for the company in a report on Monday, May 13th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $11.50.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.